Seattle Genetics on a roll with sixth Adcetris approval

16 November 2018

Shares in Seattle Genetics (Nasdaq: SGEN) are up nearly 5% and climbing today after the firm announced a new approval for Adcetris (brentuximab vedotin), shortly after revealing the US regulator had granted the therapy Breakthrough Designation in the same indication.

The approval is for a combination of the antibody-drug conjugate and chemotherapy for certain adults with peripheral T-cell lymphomas (PTCL), in the first-line setting.

The green light was given based on the successful outcome of the Phase III ECHELON-2 study, and was granted in record time under a US Food and Drug Administration pilot program.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK